Bartlett M S, Edlind T D, Lee C H, Dean R, Queener S F, Shaw M M, Smith J W
Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis 46202.
Antimicrob Agents Chemother. 1994 Aug;38(8):1834-7. doi: 10.1128/AAC.38.8.1834.
Albendazole, a benzimidazole derivative widely used for treating helminth infections, was successfully used to treat and prevent development of Pneumocystis carinii pneumonia in transtracheally inoculated immunosuppressed mice. For treatment, 3 weeks postinoculation, albendazole at 300 and 600 mg/kg of body weight per day was administered in food for 3 weeks. For prophylaxis, albendazole was begun on the same day as inoculation at 300 mg/kg/day for 7 days, and then the dose was reduced to 150 mg/kg/day for 35 additional days. With these regimens, albendazole was effective both for treatment and prophylaxis. Both dexamethasone-immunosuppressed and L3T4+ monoclonal antibody-immunosuppressed mouse models were used, and albendazole inhibited P. carinii infection in both.
阿苯达唑是一种广泛用于治疗蠕虫感染的苯并咪唑衍生物，已成功用于治疗经气管接种的免疫抑制小鼠的卡氏肺孢子虫肺炎并预防其发展。治疗时，接种后3周，将每天300和600毫克/千克体重的阿苯达唑混入食物中给药3周。预防时，接种当天开始给予阿苯达唑，剂量为300毫克/千克/天，持续7天，然后剂量减至150毫克/千克/天，再持续35天。采用这些方案，阿苯达唑对治疗和预防均有效。使用了地塞米松免疫抑制和L3T4 +单克隆抗体免疫抑制的小鼠模型，阿苯达唑在两种模型中均抑制了卡氏肺孢子虫感染。
